These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

In the first half of 2026, Moderna, Revolution Medicines, and Axsome Therapeutics each outpaced the S&P 500’s >9% gain, driven by distinct biotech catalysts. Wall Street forecasts Moderna could still pull back ~40% over the next 12 months (despite up to ~10% revenue growth and an Aug. 5 FDA decision for a seasonal flu vaccine) while Revolution Medicines is expected to rise only ~2% on top-line momentum from phase 3 data (median 13.2 vs 6.7 months in metastatic pancreatic cancer). Axsome is viewed as the relative upside standout, with an average call for ~13% appreciation, supported by approvals/launches (Auvelity for agitation in Alzheimer’s) and ongoing phase 3 trials.

Analysis

The cleanest risk/reward is not “biotech broadly,” but commercialized CNS exposure versus event-driven platform optionality. AXSM has the best mix of near-term revenue visibility and incremental label expansion: agitation in Alzheimer’s can create a second launch vector on top of existing prescriptions, and the market usually rewards companies that can turn a one-product story into a two-asset growth story within 2-3 quarters. The key watch item is whether reimbursement and prescriber conversion are strong enough to show up in quarterly scripts; if not, the stock’s premium multiple can compress fast.

MRNA is a different trade: the Aug. 5 decision is a binary sentiment catalyst, but the longer-term equity debate is still about whether flu can become a meaningful offset to post-pandemic demand decay. Even if approved, the upside may be capped unless the launch shows real share capture against entrenched incumbents in a crowded vaccine market; a weak uptake print would likely trigger “show-me” skepticism and keep the stock a cash-flow story rather than a growth re-rating. RVMD remains the highest quality scientific setup, but the gap between encouraging late-stage data and durable equity value is wide; the market is paying for class validation before it has broad commercial proof.

The consensus may be overpricing speed of monetization and underpricing execution friction. For AXSM and MRNA, the first-quarter post-catalyst trade is driven by channel fill, payer access, and sell-side model resets, not headline approval alone. For RVMD, the contrarian risk is that even exceptional data in a narrow cancer setting still supports a premium valuation, but not necessarily an open-ended run if filing timing slips or the addressable population proves smaller than bulls expect.

Key Decisions for Investors

• Long AXSM vs short XBI for a 1-3 month relative-value trade: AXSM has the cleanest near-term fundamental inflection, while XBI remains vulnerable to multiple compression if the group rotates away from binary biotech.
• If willing to take binary event risk, buy limited-risk AXSM call spreads into the next quarterly print and the Alzheimer’s agitation launch data; thesis fails if scripts and reimbursement do not inflect over 2 quarters.
• Treat MRNA as a catalyst watch, not a high-conviction long: buy only on post-approval weakness if the Aug. 5 decision is positive but the market sells the news; otherwise avoid chasing before launch uptake is visible.
• For RVMD, use upside participation via call spreads rather than outright equity into submission/review milestones; the main risk is timing slippage, not science, and valuation can stall if the path to approval elongates.